The life cycle of extracellular vesicles in prostate cancer: from biogenesis and homing, to functional relevance

Acronym

proEVLifeCycle

Description of the granted funding

The prostate cancer Extracellular Vesicle LifeCycle (proEVLifeCycle) network is an innovative, multidisciplinary training program focused on understanding the biology, biomarker potential and function of extracellular vesicles (EVs) to resolve unmet clinical needs of prostate cancer (PCa). It is within this realm, that we will equip early stage researchers with the knowledge, tools and a creative ethos to be independent scientists, leaders, and drivers of innovation. The lifecycle of EVs is poorly understood and their potential as non-invasive biomarkers and therapy target/agents, a growing area of interest. This research can perfectly be integrated with the high need for novel biomarkers and therapy targets for PCa. Any relief in the burden of this disease will have major impact on the huge socio-economic problems for patients, families, caregivers and society. The ambitious scientific objectives are to unravel the mysteries of EV biogenesis, homing and uptake to explain how vesicles operate in disease processes; their heterogeneity, their molecular complexity, the biological functions they drive, their local and systemic dissemination and how these may be manipulated. Using state-of-the-art, network-wide shared model systems, imaging and profiling tools, and systems biology, the program will enlighten the lifecycle of EVs and identify novel EV biomarkers and PCa therapy targets to address the unmet clinical needs. Our original network of 7 academic and 3 company beneficiaries and 11 partners, provides optimal scientific training, crosssectoral awareness, entrepreneurship skills, communication in the modern age, extensive opportunities for mobility and patient-facing experiences. We herein meet identified EU-skills gaps providing well-rounded and inventive experts primed for influential careers, contributing to patient well-being and economic prosperity within the EU.
Show more

Starting year

2019

End year

2023

Granted funding

280 805.76 €
Participant
GenomeScan B.V. (NL)
265 619.88 €
Participant
ANAXOMICS BIOTECH, S.L. (ES)
250 904.88 €
Participant
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS (ES)
250 904.88 €
Participant
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES)
250 904.88 €
Participant
AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH (AT)
264 207.24 €
Participant
UNIVERSITAIR MEDISCH CENTRUM UTRECHT (NL)
265 619.88 €
Participant
CARDIFF UNIVERSITY (UK)
303 172.56 €
Participant
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL)
265 619.88 €
Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR)
274 802.04 €
Participant

Amount granted

2 672 562 €

Funder

European Union

Funding instrument

Marie Skłodowska-Curie Innovative Training Networks (ITN)

Framework programme

Horizon 2020 Framework Programme

Call

Programme part
EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (5220)
Fostering new skills by means of excellent initial training of researchers (5221)
Topic
Innovative Training Networks (MSCA-ITN-2019)
Call ID
H2020-MSCA-ITN-2019

Other information

Funding decision number

860303

Identified topics

cancer